About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Primary Care
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
J
2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discussion
By
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
FEATURING
Jason Brayer
February 14, 2022
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
23:18
Oncology Data Advisor
Can Diet and Nutrition Impact Multiple Myeloma Outcomes?
Feat.
U. Shah,
R. Banerjee
10:50
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …
Feat.
A. Jakubowiak
33:28
Cleveland Clinic Taussig Cancer Institute
Management of Relapsed/Refractory Multiple Myeloma
Feat.
F. Anwer
26:18
Morie Gertz
Treatment of Relapsed Myeloma: Overview of Approved Drugs & Opti…
04:41
Joshua Richter
Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Tri…
22:41
Ehsan Malek
Importance and Prospect of Maintenance Treatment in Post-SCT MM Pati…
15:12
Yale Cancer Center
ASH 2021: Cellular Therapies in Myeloma
Feat.
N. Bar
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases
MM - Overview of Trials Presented at ASH 2018
Feat.
A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference
Evolution of Myeloma Induction Regimens
Feat.
S. Holstein
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patient…
Feat.
T. Martin
05:09
Association of Community Cancer Centers (ACCC)
72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Di…
Feat.
K. Maples
31:09
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
2022 Updates on BCMA CAR T-Cell for MM: Real World Experience and Future P…
Feat.
M. Alsina
15:11
Ajay Nooka
Early Relapse: Choosing Among Different Second Line Regimens in Myel…
13:12
ASH 2021 Conference Coverage on VuMedi
ASH 2021: Addressing Current Questions and Controversies in the Mana…
Feat.
M. Gertz
10:47
SOHO Highlights: State of the Art and Next Questions
Surveying the Induction and Maintenance Therapy Landscape in Newly D…
Feat.
S. Lonial
06:31
2nd SOHO Italian Conference
Treatment Options for the R/R MM Patients: A Review of the Current D…
Feat.
K. Anderson
18:43
7th Eurasian Hematology Oncology Summit
2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…
Feat.
E. Terpos
11:10
Yale Cancer Center
Yale Cancer Center Multiple Myeloma and Gammopathies: Translational …
Feat.
N. Neparidze
25:24
Extracellular Vesicles and Their Role in Patients With Multiple Myeloma
Biologically Based Therapies for MM: Surveying Novel Options
Feat.
K. Anderson
12:53
2nd SOHO Italian Conference
Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…
Feat.
N. Bolli